ATE256143T1 - 2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen - Google Patents

2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen

Info

Publication number: ATE256143T1
Authority: AT; Austria
Prior art keywords: phosphoramidites; production; alkyl; alkyl nucleosides; guanosine
Prior art date: 1992-07-23

Application number

AT93917287T

Other languages

English (en)

Inventor

Daniel Peter Claude Mcgee

Phillip Dan Cook

Charles John Guinosso

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-23

Filing date

1993-07-20

Publication date

2003-12-15

1992-07-23 Priority claimed from US07/918,362 external-priority patent/US5506351A/en

1992-10-27 Priority claimed from US07/967,267 external-priority patent/US7101993B1/en

1993-07-20 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

2003-12-15 Application granted granted Critical

2003-12-15 Publication of ATE256143T1 publication Critical patent/ATE256143T1/de

Links

238000000034 method Methods 0.000 title abstract 4
239000002777 nucleoside Substances 0.000 title 1
150000008300 phosphoramidites Chemical class 0.000 title 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Natural products C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 abstract 3
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 abstract 2
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 abstract 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 abstract 2
229940029575 guanosine Drugs 0.000 abstract 2
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 abstract 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 abstract 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 abstract 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract 1
229940045145 uridine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT93917287T 1992-07-23 1993-07-20 2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen ATE256143T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US07/918,362 US5506351A (en)	1992-07-23	1992-07-23	Process for the preparation of 2'-O-alkyl guanosine and related compounds
US07/967,267 US7101993B1 (en)	1990-01-11	1992-10-27	Oligonucleotides containing 2′-O-modified purines
US96884992A	1992-10-30	1992-10-30
PCT/US1993/006807 WO1994002501A1 (en)	1992-07-23	1993-07-20	Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof

Publications (1)

Publication Number	Publication Date
ATE256143T1 true ATE256143T1 (de)	2003-12-15

Family

ID=27420643

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT02076058T ATE299509T1 (de)	1992-07-23	1993-07-20	Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen
AT93917287T ATE256143T1 (de)	1992-07-23	1993-07-20	2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT02076058T ATE299509T1 (de)	1992-07-23	1993-07-20	Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen

Country Status (7)

Country	Link
EP (2)	EP1223173B1 (de)
JP (3)	JP3015464B2 (de)
AT (2)	ATE299509T1 (de)
AU (1)	AU4684993A (de)
CA (1)	CA2140428C (de)
DE (2)	DE69333344T2 (de)
WO (1)	WO1994002501A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6399754B1 (en)	1991-12-24	2002-06-04	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
ATE177430T1 (de) *	1993-05-12	1999-03-15	Novartis Erfind Verwalt Gmbh	Nukleoside und oligonukleotide mit 2'- ethergruppen
US5955591A (en) *	1993-05-12	1999-09-21	Imbach; Jean-Louis	Phosphotriester oligonucleotides, amidites and method of preparation
AT407639B (de) *	1993-12-13	2001-05-25	Christian Dr Noe	Modifizierte oligonukleotide, verfahren zu ihrer herstellung und verwendung als wirkstoffe zur herstellung von arzneimitteln
US5756707A (en) *	1994-12-13	1998-05-26	Perseptive Biosystems, Inc.	Method of making 2'-O-alkyl pyrimidine ribonucleosides
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
NZ331217A (en)	1996-02-14	2000-02-28	Novartis Ag	Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) *	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
CA2256765A1 (en) *	1996-06-06	1997-12-11	Novartis Ag	2'-substituted nucleosides and oligonucleotide derivatives
JP2000514307A (ja) *	1996-07-16	2000-10-31	ジェン―プローブ・インコーポレーテッド	増加した標的特異的ｔ▲下ｍ▼を持つ修飾オリゴヌクレオチドを用いた核酸配列の検出および増幅のための方法
US7070925B1 (en)	1996-07-16	2006-07-04	Gen-Probe Incorporated	Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe
US6025133A (en) *	1996-12-30	2000-02-15	Gen-Probe Incorporated	Promoter-sequestered oligonucleoside and method of use
US6576752B1 (en) *	1997-02-14	2003-06-10	Isis Pharmaceuticals, Inc.	Aminooxy functionalized oligomers
US6127533A (en) *	1997-02-14	2000-10-03	Isis Pharmaceuticals, Inc.	2'-O-aminooxy-modified oligonucleotides
US6172209B1 (en)	1997-02-14	2001-01-09	Isis Pharmaceuticals Inc.	Aminooxy-modified oligonucleotides and methods for making same
DE19741715A1 (de) *	1997-09-22	1999-03-25	Hoechst Ag	Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
US6673912B1 (en)	1998-08-07	2004-01-06	Isis Pharmaceuticals, Inc.	2′-O-aminoethyloxyethyl-modified oligonucleotides
US6043352A (en)	1998-08-07	2000-03-28	Isis Pharmaceuticals, Inc.	2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
US6403779B1 (en)	1999-01-08	2002-06-11	Isis Pharmaceuticals, Inc.	Regioselective synthesis of 2′-O-modified nucleosides
WO2001002608A1 (en) *	1999-07-06	2001-01-11	Isis Pharmaceuticals, Inc.	Oligonucleotides incorporating both 2-aminoadenine and 5-substituted pyrimidines
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
JP3596669B2 (ja) *	2000-08-08	2004-12-02	ヤマサ醤油株式会社	２’−ｏ−アルキルグアノシンの製造法
EP2221376B1 (de)	2001-06-21	2012-11-21	Isis Pharmaceuticals, Inc.	Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
NZ585001A (en)	2001-10-09	2011-08-26	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expression
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
US7229976B2 (en)	2002-09-26	2007-06-12	Isis Pharmaceuticals, Inc.	Modulation of forkhead box O1A expression
AU2003291755A1 (en)	2002-11-05	2004-06-07	Isis Pharmaceuticals, Inc.	Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
SI1569695T1 (sl)	2002-11-13	2013-08-30	Genzyme Corporation	Protismiselna modulacija ekspresije apolipoproteina B
EP2336318B1 (de)	2002-11-13	2013-04-24	Genzyme Corporation	Antisense-modulation von apolipoprotein-b-expression
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
JP2009531283A (ja)	2006-02-02	2009-09-03	アラーガン、インコーポレイテッド	眼系疾患の処置のための組成物および方法
DE102006017600A1 (de) *	2006-02-09	2007-08-16	Friedel, Ruthard, Dr.	Nucleosidanaloga als Genexpressionsregulatoren bei Viren
EP1820804A1 (de) *	2006-02-20	2007-08-22	Humboldt-Universität zu Berlin	Lipophile Oligonukleotide
JP5070550B2 (ja) *	2006-04-13	2012-11-14	国立大学法人北海道大学	抗ヘルペスウイルス活性を有するヌクレオシド誘導体
ES2911034T3 (es)	2006-08-08	2022-05-17	Univ Bonn Rheinische Friedrich Wilhelms	Estructura y uso de oligonucleótidos 5' fosfato
US11078262B2 (en)	2007-04-30	2021-08-03	Allergan, Inc.	High viscosity macromolecular compositions for treating ocular conditions
WO2009141146A1 (en)	2008-05-21	2009-11-26	Gunther Hartmann	5' triphosphate oligonucleotide with blunt end and uses thereof
EP2508530A1 (de)	2011-03-28	2012-10-10	Rheinische Friedrich-Wilhelms-Universität Bonn	Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
SG10201913554YA (en)	2011-12-22	2020-03-30	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
EP2712870A1 (de)	2012-09-27	2014-04-02	Rheinische Friedrich-Wilhelms-Universität Bonn	Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
GB201410693D0 (en)	2014-06-16	2014-07-30	Univ Southampton	Splicing modulation
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
AU2015327836B2 (en)	2014-10-03	2021-07-01	Cold Spring Harbor Laboratory	Targeted augmentation of nuclear gene output
CN108603230A (zh)	2015-10-09	2018-09-28	南安普敦大学	基因表达的调节与蛋白质表达失调的筛选
US11096956B2 (en)	2015-12-14	2021-08-24	Stoke Therapeutics, Inc.	Antisense oligomers and uses thereof
WO2017106377A1 (en)	2015-12-14	2017-06-22	Cold Spring Harbor Laboratory	Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
KR102318434B1 (ko)	2017-08-25	2021-11-01	스톡 테라퓨틱스, 인크.	병태 및 질환 치료용 안티센스 올리고머
CA3099280A1 (en)	2018-05-04	2019-11-07	Stoke Therapeutics, Inc.	Methods and compositions for treatment of cholesteryl ester storage disease
MX2020011570A (es)	2018-05-07	2020-11-24	Alnylam Pharmaceuticals Inc	Administracion extrahepatica.
CN108822174A (zh) *	2018-08-29	2018-11-16	上海兆维科技发展有限公司	新型核苷修饰物2’-eoe-鸟嘌呤核苷及其制备方法
AU2020227825B2 (en)	2019-02-27	2026-03-26	Stoke Therapeutics, Inc.	Antisense oligomers for treatment of conditions and diseases
IL293327B2 (en) *	2019-11-27	2026-04-01	Alnylam Pharmaceuticals Inc	Synthesis of 3'-RNA oligonucleotides
CN115867657A (zh)	2020-05-11	2023-03-28	斯托克制药公司	用于治疗疾患和疾病的opa1反义寡聚物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR927003044A (ko)	1990-01-11	1992-12-17	크리스토퍼 케이. 미라벨리	Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법
DE4037363A1 (de)	1990-04-09	1991-10-10	Europ Lab Molekularbiolog	2-0-alkylnukleotide sowie polymere, die solche nukleotide enthalten
DE4110085A1 (de) *	1991-03-27	1992-10-01	Boehringer Ingelheim Int	2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide
US5214135A (en) *	1991-08-30	1993-05-25	Chemgenes Corporation	N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides

1993
- 1993-07-20 AT AT02076058T patent/ATE299509T1/de not_active IP Right Cessation
- 1993-07-20 EP EP02076058A patent/EP1223173B1/de not_active Expired - Lifetime
- 1993-07-20 WO PCT/US1993/006807 patent/WO1994002501A1/en not_active Ceased
- 1993-07-20 DE DE69333344T patent/DE69333344T2/de not_active Expired - Lifetime
- 1993-07-20 DE DE69333842T patent/DE69333842T2/de not_active Expired - Lifetime
- 1993-07-20 CA CA002140428A patent/CA2140428C/en not_active Expired - Lifetime
- 1993-07-20 AU AU46849/93A patent/AU4684993A/en not_active Abandoned
- 1993-07-20 EP EP93917287A patent/EP0651759B1/de not_active Expired - Lifetime
- 1993-07-20 AT AT93917287T patent/ATE256143T1/de not_active IP Right Cessation
- 1993-07-20 JP JP6504646A patent/JP3015464B2/ja not_active Expired - Lifetime
1997
- 1997-07-18 JP JP9194153A patent/JPH1087689A/ja active Pending
1999
- 1999-10-15 JP JP11293153A patent/JP2000095793A/ja not_active Ceased

Also Published As

Publication number	Publication date
EP0651759A1 (de)	1995-05-10
CA2140428C (en)	2003-07-08
EP0651759A4 (de)	1995-10-25
WO1994002501A1 (en)	1994-02-03
JP2000095793A (ja)	2000-04-04
JP3015464B2 (ja)	2000-03-06
DE69333842T2 (de)	2006-04-27
ATE299509T1 (de)	2005-07-15
EP0651759B1 (de)	2003-12-10
EP1223173B1 (de)	2005-07-13
EP1223173A3 (de)	2003-04-16
JPH1087689A (ja)	1998-04-07
AU4684993A (en)	1994-02-14
CA2140428A1 (en)	1994-02-03
DE69333842D1 (de)	2005-08-18
JPH07508042A (ja)	1995-09-07
EP1223173A2 (de)	2002-07-17
DE69333344D1 (de)	2004-01-22
DE69333344T2 (de)	2004-10-07

Legal Events

Date	Code	Title	Description
2004-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE256143T1 (de)	2003-12-15	2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen
HUT62010A (en)	1993-03-29	Process for producing oligonucleotide analogs comprising terminal 3 - 3, or 5 - 5- intermolecular bonds
GB2228479B (en)	1993-10-20	2',3'-dideoxy purine nucleosides and process for the preparation thereof
DE59100830D1 (de)	1994-02-24	Verfahren zur Herstellung von 3-Aminomethyl-3,5,5,-trimethyl-cyclohexylamin.
DE3889393D1 (de)	1994-06-09	Verfahren zur Herstellung von 2,2,6,6-Tetramethyl-4-piperidylaminen.
ATE73758T1 (de)	1992-04-15	2,2-difluorcyclopropylethanderivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel.
EP0266168A3 (de)	1990-10-03	Zusammensetzungen und Verfahren zur Herstellung von Oligonukleotiden, deren 5' Ende phosphoryliert ist
FI885153A0 (fi)	1988-11-09	Menetelmä terapeuttisesti aktiivisten 2',3'-dideoksi-2'-fluorinukleosidien valmistamiseksi
NO171641C (no)	1993-04-14	Analogifremgangsmaate for fremstilling av 6-substituert-2',3'-dideoksynukleosider
DE3884644D1 (de)	1993-11-11	Verfahren zur Herstellung von 5'-Inosinsäure.
DE3789466D1 (de)	1994-05-05	3,7-Disubstituierte-3-Cephemverbindungen und Verfahren zu ihrer Herstellung.
FI885094A7 (fi)	1989-05-08	Menetelmä terapeuttisesti käyttökelpoisen 2',3'-dideoksi-3'-fluoripyrimidiini- tai -puriininukleosidin valmistamiseksi
FI881413A7 (fi)	1988-09-26	Menetelmä 3'-atsido-3'-deoksitymidiinin valmistamiseksi.
EP0251489A3 (en)	1989-01-25	Process for producing 5'-guanylic acid
IL110968A0 (en)	1994-11-28	Nucleosides, nucleotides and oligonucleotides comprising tris-4,4',4"-tert-butylphenylmethyl, as protected group and their preparation
IE45285L (en)	1977-12-03	Polyribonucleotides.
EP0521463A3 (en)	1993-04-14	Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
DE3887212D1 (de)	1994-03-03	Verfahren zur Herstellung von Derivaten von 6,7-Diazyl-7-desacetylforskolin.
DE69004042D1 (de)	1993-11-25	2,4-Pentandion-1,5-Disulfonsäure und Verfahren zu ihrer Herstellung.
KR960701075A (ko)	1996-02-24	신규 2'-메틸리덴 뉴클레오티드 화합물, 그의 제조 방법 및 그의 약학적 용도[novel 2'-methylidenenucleotide compound, process for producing the same, and pharmaceutical use thereof]
DE69206765D1 (de)	1996-01-25	Verfahren zur herstellung von 2',3'-dideoxy-beta-nucleosiden
IL93001A0 (en)	1990-09-17	Purine nucleosides and nucleotides,processes for the preparation thereof and pharmaceutical compositions containing the same
DE3887710D1 (de)	1994-03-24	1-(3,5-Di-0-benzoyl-2-deoxy-beta-D-threo-pentofuranosyl)Thymine und Verfahren zu deren Herstellung.
EP0406436A4 (en)	1992-04-22	Process for preparing 5'-inosinic acid
DE3887626D1 (de)	1994-03-17	2-Oxa-isocephem-Verbindungen, diese enthaltende Zusammensetzungen und Verfahren zu deren Herstellung.